A study to assess the effects of DPP-4 inhibition on insulin sensitivity in type 2 diabetes.

Trial Profile

A study to assess the effects of DPP-4 inhibition on insulin sensitivity in type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2012

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 04 May 2012 Actual patient number changed from 18 to 12 as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual end date (1 Dec 2005) added as reported by ClinicalTrials.gov.
    • 20 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top